ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma. It has license agreements with Board of Trustees of Leland Stanford Junior University. The company was incorporated in 2015 and is headquartered in South San Francisco, California.…
ALX Oncology's Two Clinical Readouts Offer Potential Upside, UBS Says
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
ALX Oncology Holdings (NASDAQ: ALXO) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 49 employees.
The shares were at 1.060 USD on 20 November 2026, down 23.2% over 52 weeks. Its 52-week range is 0.8617 USD to 2.660 USD: the price is 60.2% below the high and 23.0% above the low.
Its market capitalisation is 137.03M USD.
ALX Oncology Holdings reports return on equity of -391.4% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 136.51M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 25 February 2027.